Researchers describe how an approved arthritis drug successfully treated 6 patients with moderate to severe eczema that was not responding to conventional treatments.

Janssen-Cilag International NV ("Janssen") has announced that the European Commission (EC) has approved STELARA® (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis in...

A mouse study identifies the serotonin receptor HTR7 as a potential new target for therapies to treat eczema and other chronic itching conditions.

A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent...

LEO Pharma A/S has announced that new data being presented at the 23rd World Congress of Dermatology shows aerosol foam Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5...

A*STAR's Genome Institute of Singapore (GIS) led an international team of researchers from Singapore, China, USA and Europe to conduct the world's first large-scale, trans-ethnic, genome-wide...

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.

Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4)...

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") obtaining unexpected results: drugs used to treat hypertension (high blood pressure)...

Immunotherapy with natural signaling substance relieves skin conditionA three-character code brings relief to patients with psoriasis and sheds light on complex immunoregulation processes: IL-4...